MedTrace Logo

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

NCT06617481 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-10-24

No results posted yet for this study

Summary

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.

The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Conditions

  • Prostate Cancer (Post Prostatectomy)

Interventions

DRUG

18F-rhPSMA-7.3 (Posluma)

PET Scan using Posluma for detection of early recurrence of prostate cancer.

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • AdventHealth

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2027-09-05
Completion
2027-10-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06617481 on ClinicalTrials.gov